Latest Vaccine News

Experts concerned COVID-19 vaccine may not be as effective for obese people
https://abc13.com/health/covid-19-vaccine-may-not-be-as-effective-for-obese-people/6369479/

As clinical trials for a COVID-19 vaccine move forward, some experts are worried it may not be as effective for obese people, which includes more than a third of Americans according to the CDC.

"We know from other vaccines that have been tested in obese populations that these individuals don't respond as well to these vaccines," said Dr. Matthew B. Laurens, a lead investigator at the University of Maryland for one of the country's most advanced coronavirus vaccine trials by Moderna Therapeutics in a report by ABC News.

In 2017, researchers at the University of North Carolina at Chapel Hill found that vaccinated adults were twice as likely to be infected with the flu or flu-like illnesses compared to non-obese adults. The study suggested that while medical experts are still trying to fully understand the phenomenon, there are some theories behind the disparities.

"The differences that are seen in the vaccine response in obese people were really noticed as early as 1985," said medical director of diagnostic biology at Houston Methodist Hospital Dr. Wesley Long.

"There's a variety of theories. Everything from the fact that maybe the needles that we use to give vaccines are too short to effectively get into the muscle to deliver the vaccine in obese people to perhaps, because of a larger body mass, maybe a larger dose of vaccine needs to be used and, also, that perhaps it's a sort of chronic inflammatory state that's present in people who are obese and may interfere with the immune response to vaccines."

Historically, many clinical trials for vaccines have excluded obese people due to chronic medical conditions that could alter trial results. However, Long said that's beginning to change.

"We don't have any data, as far as I know, about COVID-19 vaccines, but this is one of the reasons why you have to do those large phase three clinical trials," said Dr. Peter Hotez, the dean of the National School of Tropical Medicine at Baylor College of Medicine. "You can't rush them, because you want to be able to look at different populations, and there are different vaccines rolling out through Operation Warp Speed. So some vaccines may work better in some populations than others."

Doctors say it is still critical for everyone to get vaccinated to minimize any risks for complications caused by infection.

"It's really our best hope at controlling this pandemic and even if obese people have perhaps less of a protective response," Long said. "One thing we know with the flu vaccine is that it's very good, and with influenza, it's very good at preventing hospitalizations. So even if you are obese, you are much better off having had the flu shot and having some response than not having the flu shot because, again obese individuals are at higher risk for complications from influenza and from COVID-19. They tend to have other comorbidities that make them at higher risk of infections, so having some amount of protective response from vaccinations is going to be more beneficial than having no response at all."

Oh definitely. It is clear as day at this point that anyone who has glucose management issues is at higher risk and if a person is obese they are either diabetic or pre-diabetic.

In addition- and this is no small factor- fat cells in and of themselves are inflammatory and place an inflammation load on to the body in the best of times. That is why- or a partial explanation- obesity is linked to so many other diseases beyond just heart disease.

All these people running around saying that they or so and so are "healthy even though they are obese" are misguided. No they are not.

A vaccine nevertheless would help, it just can't do the whole job for them.
 
Last edited:
Last edited:
https://scitechdaily.com/single-dos...nfection-in-mice-works-better-than-injection/

Interesting.

Vaccine delivery via nose seems particularly effective.

Better get the chemtrail planes warmed up to defeat the trump humper anti-vaxxers. On thing I know for sure that when he loses the hastily prepared vaccines he oversaw will become democrat poison in his tweets.

FB_IMG_1598236825610.jpg
 
COVID-19 Vaccine May Pit Science Against Politics
https://www.npr.org/sections/health...d-19-vaccine-may-pit-science-against-politics

Under normal circumstances, it could take years — if not decades — to bring a new vaccine to market. The COVID-19 pandemic has changed all that. In May, the Trump Administration launched Operation Warp Speed with the goal of delivering initial doses of a safe and effective vaccine by January, 2021 --shortening the development time from years to months.

Some worry that to meet that ambitious schedule, the Administration might cut important scientific corners. They fear that President Trump could announce an "October surprise"-- declaring that a vaccine works before it has passed scientific muster in order to enhance his reelection chances.

After all, the President ballyhooed supposed virtues of hydroxychloroquine when most scientists thought the drug was not helpful, and maybe downright dangerous in treating or preventing coronavirus infections. This week, the FDA granted authorization for using convalescent plasma as a treatment for COVID-19, a move some say was done under political pressure from the White House.

FDA officials have maintained that all their decisions are based on science, not politics.

In June, the agency released guidance for what it would require before granting any kind of approval for the COVID-19 vaccine.

The guidance states that at a minimum, the FDA wants to see any vaccine tested in thousands of people so that any relatively rare side effects can be caught, and to see if the vaccine is actually preventing disease. The agency also says the vaccine doesn't have to prevent 100% of disease to get a green light; just 50% would be sufficient.

How long it would take to show that depends on several factors, including how fast volunteers can be enrolled in trials and how much virus is circulating where the trials are taking place. Certainly it's a process that would take months.

The Trump Administration has vowed to cut red tape to speed the approval process, and the normal process does require a lot of data and a lot of paperwork.

But the FDA has also said it would consider granting something called an Emergency Use Authorization, or EUA, to the makers of a vaccine candidate that appeared to be safe and effective.

That's where critics worry political influence could creep in.

"The EUA rules are loose," says Paul Offit, a vaccine developer at Children's Hospital of Philadelphia and a member of the FDA's Vaccines and Related Biological Products Advisory Committee. Usually, the FDA would rely on the independent scientists on that committee to advise it about important decisions concerning new therapies and vaccines. Offit worries the FDA could be pressured into issuing an EUA with little or no scrutiny of that decision.

It's a concern echoed by the leadership of the Infectious Diseases Society of America and HIV Medicine Association. In a letter to the FDA, they write, "We want to underscore that it is critical that FDA ensures sufficient safety and efficacy data are available and have been reviewed by internal as well as independent experts prior to granting an EUA."

FDA Commissioner Stephen Hahn has tried to assure skeptics that won't happen. He wrote an editorial dated Aug. 7, 2020 in the medical journal JAMA.

"The physician leadership of the U.S. Food and Drug Administration (including the authors of this Viewpoint) unequivocally state that candidate COVID-19 vaccines will be reviewed according to the established legal and regulatory standards for medical products," Hahn wrote.

The editorial continues: "Given the widespread potential use of a COVID-19 vaccine, transparent discussion at FDA's Vaccines and Related Biological Products Advisory Committee will be needed prior to vaccine authorization or licensure to ensure clear public understanding of the evidence supporting vaccine safety and efficacy."

Even if the evidence is made public, there could still be a robust scientific debate over whether a vaccine is ready for approval. Opinions will vary about just how convincing the data are, and whether the reported effectiveness is really adequate to rein in the pandemic.

The shorter the time allotted for testing, the less likely there will be ironclad evidence that a vaccine is effective. What's more, the fewer people in whom the vaccine is tested, the less likely the testing will reveal rare but fatal side effects. Shorter testing periods also mean there's less certainty about how long any protective effect from a vaccine will last.

So there are bound to be critics of any decision the FDA makes.

Paul Offit says making the right decision is critical.

"We have two ways out of this pandemic. One is hygienic measures — which we don't seem very good at — and two is the vaccine," he says.

"Don't screw this up. The vaccine is our best way out of it at this point. And to shake the American confidence further with either an unsafe or ineffective vaccine would be, I think, a disaster."

At least two other countries seem to have slighted science in making decisions about vaccines. For example, Russian President Vladimir Putin announced on Aug. 11 that regulators in that country would approve a Russian-made vaccine — long before it had undergone the kind of evaluation scientists say is essential. China also reportedly began giving an unproven vaccine to its citizens in July.
 
COVID-19 Vaccine May Pit Science Against Politics
https://www.npr.org/sections/health...d-19-vaccine-may-pit-science-against-politics

Under normal circumstances, it could take years — if not decades — to bring a new vaccine to market. The COVID-19 pandemic has changed all that. In May, the Trump Administration launched Operation Warp Speed with the goal of delivering initial doses of a safe and effective vaccine by January, 2021 --shortening the development time from years to months.

Some worry that to meet that ambitious schedule, the Administration might cut important scientific corners. They fear that President Trump could announce an "October surprise"-- declaring that a vaccine works before it has passed scientific muster in order to enhance his reelection chances.

After all, the President ballyhooed supposed virtues of hydroxychloroquine when most scientists thought the drug was not helpful, and maybe downright dangerous in treating or preventing coronavirus infections. This week, the FDA granted authorization for using convalescent plasma as a treatment for COVID-19, a move some say was done under political pressure from the White House.

FDA officials have maintained that all their decisions are based on science, not politics.

In June, the agency released guidance for what it would require before granting any kind of approval for the COVID-19 vaccine.

The guidance states that at a minimum, the FDA wants to see any vaccine tested in thousands of people so that any relatively rare side effects can be caught, and to see if the vaccine is actually preventing disease. The agency also says the vaccine doesn't have to prevent 100% of disease to get a green light; just 50% would be sufficient.

How long it would take to show that depends on several factors, including how fast volunteers can be enrolled in trials and how much virus is circulating where the trials are taking place. Certainly it's a process that would take months.

The Trump Administration has vowed to cut red tape to speed the approval process, and the normal process does require a lot of data and a lot of paperwork.

But the FDA has also said it would consider granting something called an Emergency Use Authorization, or EUA, to the makers of a vaccine candidate that appeared to be safe and effective.

That's where critics worry political influence could creep in.

"The EUA rules are loose," says Paul Offit, a vaccine developer at Children's Hospital of Philadelphia and a member of the FDA's Vaccines and Related Biological Products Advisory Committee. Usually, the FDA would rely on the independent scientists on that committee to advise it about important decisions concerning new therapies and vaccines. Offit worries the FDA could be pressured into issuing an EUA with little or no scrutiny of that decision.

It's a concern echoed by the leadership of the Infectious Diseases Society of America and HIV Medicine Association. In a letter to the FDA, they write, "We want to underscore that it is critical that FDA ensures sufficient safety and efficacy data are available and have been reviewed by internal as well as independent experts prior to granting an EUA."

FDA Commissioner Stephen Hahn has tried to assure skeptics that won't happen. He wrote an editorial dated Aug. 7, 2020 in the medical journal JAMA.

"The physician leadership of the U.S. Food and Drug Administration (including the authors of this Viewpoint) unequivocally state that candidate COVID-19 vaccines will be reviewed according to the established legal and regulatory standards for medical products," Hahn wrote.

The editorial continues: "Given the widespread potential use of a COVID-19 vaccine, transparent discussion at FDA's Vaccines and Related Biological Products Advisory Committee will be needed prior to vaccine authorization or licensure to ensure clear public understanding of the evidence supporting vaccine safety and efficacy."

Even if the evidence is made public, there could still be a robust scientific debate over whether a vaccine is ready for approval. Opinions will vary about just how convincing the data are, and whether the reported effectiveness is really adequate to rein in the pandemic.

The shorter the time allotted for testing, the less likely there will be ironclad evidence that a vaccine is effective. What's more, the fewer people in whom the vaccine is tested, the less likely the testing will reveal rare but fatal side effects. Shorter testing periods also mean there's less certainty about how long any protective effect from a vaccine will last.

So there are bound to be critics of any decision the FDA makes.

Paul Offit says making the right decision is critical.

"We have two ways out of this pandemic. One is hygienic measures — which we don't seem very good at — and two is the vaccine," he says.

"Don't screw this up. The vaccine is our best way out of it at this point. And to shake the American confidence further with either an unsafe or ineffective vaccine would be, I think, a disaster."

At least two other countries seem to have slighted science in making decisions about vaccines. For example, Russian President Vladimir Putin announced on Aug. 11 that regulators in that country would approve a Russian-made vaccine — long before it had undergone the kind of evaluation scientists say is essential. China also reportedly began giving an unproven vaccine to its citizens in July.
Way too lengthy to read---and---get off the same old crap narrative please. You are showing yourself to be a fool.
 
Way too lengthy to read---and---get off the same old crap narrative please. You are showing yourself to be a fool.

Thank you for confirming your inability to read..... or learn.

I have neither the time nor the crayons to explain this to you properly.
 
Scientists see downsides to top COVID-19 vaccines from Russia, China
https://www.reuters.com/article/us-...d-19-vaccines-from-russia-china-idUSKBN25R19H

High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.

CanSino Biologics’ (6185.HK) vaccine, approved for military use in China, is a modified form of adenovirus type 5, or Ad5. The company is in talks to get emergency approval in several countries before completing large-scale trials, the Wall Street Journal reported last week.

A vaccine developed by Moscow’s Gamaleya Institute, approved in Russia earlier this month despite limited testing, is based on Ad5 and a second less common adenovirus.

“The Ad5 concerns me just because a lot of people have immunity,” said Anna Durbin, a vaccine researcher at Johns Hopkins University. “I’m not sure what their strategy is ... maybe it won’t have 70% efficacy. It might have 40% efficacy, and that’s better than nothing, until something else comes along.”

Vaccines are seen as essential to ending the pandemic that has claimed over 845,000 lives worldwide. Gamaleya has said its two-virus approach will address Ad5 immunity issues.

Both developers have years of experience and approved Ebola vaccines based on Ad5. Neither CanSino nor Gamaleya responded to requests for comment.

Researchers have experimented with Ad5-based vaccines against a variety of infections for decades, but none are widely used. They employ harmless viruses as “vectors” to ferry genes from the target virus – in this case the novel coronavirus - into human cells, prompting an immune response to fight the actual virus.

But many people already have antibodies against Ad5, which could cause the immune system to attack the vector instead of responding to the coronavirus, making these vaccines less effective.

Several researchers have chosen alternative adenoviruses or delivery mechanisms. Oxford University and AstraZeneca (AZN.L) based their COVID-19 vaccine on a chimpanzee adenovirus, avoiding the Ad5 issue. Johnson & Johnson’s (JNJ.N) candidate uses Ad26, a comparatively rare strain.

Dr. Zhou Xing, from Canada’s McMaster University, worked with CanSino on its first Ad5-based vaccine, for tuberculosis, in 2011. His team is developing an inhaled Ad5 COVID-19 vaccine, theorizing it could circumvent pre-existing immunity issues.

“The Oxford vaccine candidate has quite an advantage” over the injected CanSino vaccine, he said.

Xing also worries that high doses of the Ad5 vector in the CanSino vaccine could induce fever, fueling vaccine skepticism.

“I think they will get good immunity in people that don’t have antibodies to the vaccine, but a lot of people do,” said Dr. Hildegund Ertl, director of the Wistar Institute Vaccine Center in Philadelphia.

In China and the United States, about 40% of people have high levels of antibodies from prior Ad5 exposure. In Africa, it could be has high as 80%, experts said.

HIV RISK
Some scientists also worry an Ad5-based vaccine could increase chances of contracting HIV.

In a 2004 trial of a Merck & Co (MRK.N) Ad5-based HIV vaccine, people with pre-existing immunity became more, not less, susceptible to the virus that causes AIDS.

Researchers, including top U.S. infectious diseases expert Dr. Anthony Fauci, in a 2015 paper, said the side effect was likely unique to HIV vaccines. But they cautioned that HIV incidence should be monitored during and after trials of all Ad5-based vaccines in at-risk populations.

“I would be worried about the use of those vaccines in any country or any population that was at risk of HIV, and I put our country as one of them,” said Dr. Larry Corey, co-leader of the U.S. Coronavirus Vaccine Prevention Network, who was a lead researcher on the Merck trial.

Gamaleya’s vaccine will be administered in two doses: The first based on Ad26, similar to J&J’s candidate, and the second on Ad5.

Alexander Gintsburg, Gamaleya’s director, has said the two-vector approach addresses the immunity issue. Ertl said it might work well enough in individuals who have been exposed to one of the two adenoviruses.

Many experts expressed skepticism about the Russian vaccine after the government declared its intention to give it to high-risk groups in October without data from large pivotal trials.

“Demonstrating safety and efficacy of a vaccine is very important,” said Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J’s COVID-19 vaccine. Often, he noted, large-scale trials “do not give the result that is expected or required.”
 
Back
Top